Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Clin Cancer Res. 2018 Jul 27;25(4):1233–1238. doi: 10.1158/1078-0432.CCR-18-0762

Figure 1: CTLA-4 blockade expands CD4+ and CD8+ cells.

Figure 1:

A) Stage-matched untreated (N=18) and ipilimumab (Ipi)-treated (N=16) metastatic melanoma tumor samples, and B) metastatic melanoma tumor samples (N=18) pre- and post-tremelimumab (Treme) treatment were analyzed by IHC for the presence of CD4+ and CD8+ cells. Each plot shows mean with standard deviation (SD), and each symbol represents an individual patient. Statistical significance is defined as P < 0.05.